iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 747 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2024-03-13
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-03-31 was 747.00 shares, a 93.21% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 747.00 shares, a 99.58% decline from fiscal 2022.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 178.39K shares, a 45.82% decline from fiscal 2021.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2021 was 329.25K shares.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2020 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-13 | 0.00 shares derived: sum of 3 quarters · filed 2024-03-13 | 747.00 shares 10-K · filed 2024-03-13 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-02 | 747.00 shares 10-Q · filed 2023-11-02 | 3.87K shares derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 747.00 shares 10-Q · filed 2023-08-02 | 3.87K shares derived: sum of 3 quarters · filed 2024-03-13 | 12.34K shares derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-03-31 | 747.00 shares 10-Q · filed 2023-05-04 | 3.87K shares derived: sum of 2 quarters · filed 2024-03-13 | 12.34K shares derived: sum of 3 quarters · filed 2024-03-13 | 168.13K shares derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-12-31 | 3.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 11.59K shares derived: sum of 2 quarters · filed 2024-03-13 | 167.39K shares derived: sum of 3 quarters · filed 2024-03-13 | 178.39K shares 10-K · filed 2024-03-13 | |
| 2022-09-30 | 8.47K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 164.26K shares derived: sum of 2 quarters · filed 2022-11-08 | 175.26K shares 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | 155.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 166.79K shares 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | 11.00K shares 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | 329.25K shares 10-K/A · filed 2023-03-30 | ||||
| 2021-07-31 | 189.40K shares 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |